These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

241 related items for PubMed ID: 23614561

  • 1. Oxidative stress and psoriasis: the effect of antitumour necrosis factor-α inhibitor treatment.
    Bacchetti T, Campanati A, Ferretti G, Simonetti O, Liberati G, Offidani AM.
    Br J Dermatol; 2013 May; 168(5):984-9. PubMed ID: 23614561
    [Abstract] [Full Text] [Related]

  • 2. Correlation between lipoprotein(a) and lipid peroxidation in psoriasis: role of the enzyme paraoxonase-1.
    Ferretti G, Bacchetti T, Campanati A, Simonetti O, Liberati G, Offidani A.
    Br J Dermatol; 2012 Jan; 166(1):204-7. PubMed ID: 21790517
    [Abstract] [Full Text] [Related]

  • 3. The role of inflammatory markers in assessing disease severity and response to treatment in patients with psoriasis treated with etanercept.
    Kanelleas A, Liapi C, Katoulis A, Stavropoulos P, Avgerinou G, Georgala S, Economopoulos T, Stavrianeas NG, Katsambas A.
    Clin Exp Dermatol; 2011 Dec; 36(8):845-50. PubMed ID: 21790728
    [Abstract] [Full Text] [Related]

  • 4. Paraoxonase 1 (PON1) 55 polymorphism, lipid profiles and psoriasis.
    Asefi M, Vaisi-Raygani A, Bahrehmand F, Kiani A, Rahimi Z, Nomani H, Ebrahimi A, Tavilani H, Pourmotabbed T.
    Br J Dermatol; 2012 Dec; 167(6):1279-86. PubMed ID: 22835076
    [Abstract] [Full Text] [Related]

  • 5. Effects of etanercept on C-reactive protein levels in psoriasis and psoriatic arthritis.
    Strober B, Teller C, Yamauchi P, Miller JL, Hooper M, Yang YC, Dann F.
    Br J Dermatol; 2008 Aug; 159(2):322-30. PubMed ID: 18503600
    [Abstract] [Full Text] [Related]

  • 6. Effects of etanercept treatment on lipid profile in patients with moderate-to-severe chronic plaque psoriasis: a retrospective cohort study.
    Lestre S, Diamantino F, Veloso L, Fidalgo A, Ferreira A.
    Eur J Dermatol; 2011 Aug; 21(6):916-20. PubMed ID: 21983007
    [Abstract] [Full Text] [Related]

  • 7. Psoriasis therapy and cardiovascular risk factors: a 12-week follow-up study.
    Coimbra S, Oliveira H, Reis F, Belo L, Rocha S, Quintanilha A, Figueiredo A, Teixeira F, Castro E, Rocha-Pereira P, Santos-Silva A.
    Am J Clin Dermatol; 2010 Dec 01; 11(6):423-32. PubMed ID: 20429617
    [Abstract] [Full Text] [Related]

  • 8. HDL-paraoxonase and membrane lipid peroxidation: a comparison between healthy and obese subjects.
    Ferretti G, Bacchetti T, Masciangelo S, Bicchiega V.
    Obesity (Silver Spring); 2010 Jun 01; 18(6):1079-84. PubMed ID: 19834469
    [Abstract] [Full Text] [Related]

  • 9. Etanercept improves lipid profile and oxidative stress measures in patients with juvenile idiopathic arthritis.
    De Sanctis S, Marcovecchio ML, Gaspari S, Del Torto M, Mohn A, Chiarelli F, Breda L.
    J Rheumatol; 2013 Jun 01; 40(6):943-8. PubMed ID: 23547210
    [Abstract] [Full Text] [Related]

  • 10. Treatment of erythrodermic psoriasis with etanercept.
    Esposito M, Mazzotta A, de Felice C, Papoutsaki M, Chimenti S.
    Br J Dermatol; 2006 Jul 01; 155(1):156-9. PubMed ID: 16792768
    [Abstract] [Full Text] [Related]

  • 11. Efficacy of food supplement to improve metabolic syndrome parameters in patients affected by moderate to severe psoriasis during anti-TNFα treatment.
    Skroza N, Proietti I, Bernardini N, La Viola G, Nicolucci F, Pampena R, Tolino E, Zuber S, Mancini MT, Soccodato V, Balduzzi V, Potenza C.
    G Ital Dermatol Venereol; 2013 Dec 01; 148(6):661-5. PubMed ID: 24442048
    [Abstract] [Full Text] [Related]

  • 12. Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis.
    Griffiths CE, Strober BE, van de Kerkhof P, Ho V, Fidelus-Gort R, Yeilding N, Guzzo C, Xia Y, Zhou B, Li S, Dooley LT, Goldstein NH, Menter A, ACCEPT Study Group.
    N Engl J Med; 2010 Jan 14; 362(2):118-28. PubMed ID: 20071701
    [Abstract] [Full Text] [Related]

  • 13. Genetic markers of treatment response to tumour necrosis factor-α inhibitors in the treatment of psoriasis.
    Ryan C, Kelleher J, Fagan MF, Rogers S, Collins P, Barker JN, Allen M, Hagan R, Renfro L, Kirby B.
    Clin Exp Dermatol; 2014 Jun 14; 39(4):519-24. PubMed ID: 24758522
    [Abstract] [Full Text] [Related]

  • 14. Improvement of lipid profile is accompanied by atheroprotective alterations in high-density lipoprotein composition upon tumor necrosis factor blockade: a prospective cohort study in ankylosing spondylitis.
    van Eijk IC, de Vries MK, Levels JH, Peters MJ, Huizer EE, Dijkmans BA, van der Horst-Bruinsma IE, Hazenberg BP, van de Stadt RJ, Wolbink GJ, Nurmohamed MT.
    Arthritis Rheum; 2009 May 14; 60(5):1324-30. PubMed ID: 19404933
    [Abstract] [Full Text] [Related]

  • 15. Synergistic effects of BuChE non-UU phenotype and paraoxonase (PON1) 55 M allele on the risk of systemic lupus erythematosus: influence on lipid and lipoprotein metabolism and oxidative stress, preliminary report.
    Bahrehmand F, Vaisi-Raygani A, Rahimi Z, Ahmadi R, Kiani A, Tavilani H, Vaisi-Raygani H, Pourmotabbed T.
    Lupus; 2014 Mar 14; 23(3):263-72. PubMed ID: 24399815
    [Abstract] [Full Text] [Related]

  • 16. [Clinical experience with etanercept in the treatment of psoriasis].
    Martín B, Sánchez-Carazo JL, Pérez-Ferriols A, Laguna C, Oliver V, Alegre V.
    Actas Dermosifiliogr; 2008 Sep 14; 99(7):540-5. PubMed ID: 18682167
    [Abstract] [Full Text] [Related]

  • 17. Effect of biologic therapies targeting tumour necrosis factor-α on cutaneous mesenchymal stem cells in psoriasis.
    Campanati A, Orciani M, Gorbi S, Regoli F, Di Primio R, Offidani A.
    Br J Dermatol; 2012 Jul 14; 167(1):68-76. PubMed ID: 22356229
    [Abstract] [Full Text] [Related]

  • 18. Activity of paraoxonase 1 (PON1) and its relationship to markers of lipoprotein oxidation in healthy Slovaks.
    Sumegová K, Blazícek P, Waczulíková I, Zitnanová I, Duracková Z.
    Acta Biochim Pol; 2006 Jul 14; 53(4):783-7. PubMed ID: 17106515
    [Abstract] [Full Text] [Related]

  • 19. Etanercept for psoriasis: two case reports.
    Fidalgo A, Baptista J, Rocha Páris F, Caldas Lopes L, Ferreira A.
    Int J Clin Pharmacol Res; 2005 Jul 14; 25(4):159-63. PubMed ID: 16402631
    [Abstract] [Full Text] [Related]

  • 20. Effects of etanercept on urine neopterin levels in patients with psoriasis in a controlled, open-label study.
    Koc E, Tunca M, Akgul EO, Akar A, Kurt Y, Kurumlu Z, Erbil K, Kilic S.
    J Dermatol; 2009 Apr 14; 36(4):191-6. PubMed ID: 19348656
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.